November 3 (Wed) - 5 (Fri), 2021
Jeju International Convention Center (Jeju ICC)

Development of Syndromic MDx Assay (High-multiplex Real-time PCR Test) Using Open Innovation Platform

*Korean
November 5 (Fri), 12:40-13:30, Tamna Hall (5F)

Real-time PCR is considered the gold standard method for molecular diagnostics (MDx) because of its versatility, speed, and ease of use, but the conventional technology poses limitation in the development of multiplex diagnostic tools. While high multiplex PCR technologies can be applied to develop syndromic assays which simultaneously test for multiple pathogens that cause overlapping symptoms, developing syndromic assays requires high level of chemistry technologies, know-hows, and technical skills. Seegene created artificial intelligence (AI) based digitalized development system called SGDDS and automated syndromic assay development process. Seegene’s novel algorithms, in-silico oligonucleotide design, and innovative proprietary high multiplex technologies such as DPO™, TOCE™, and MuDT™ are all incorporated in SGDDS for the development of syndromic assays. SGDDS significantly reduced the time and labor required for the development of syndromic assay and enabled world’s first open innovation assay development platform. The syndromic assay development platform will allow global experts to conveniently develop customized syndromic assays with wide application areas including not only infectious diseases, oncology, and genetics but also animal, plant, food, and R&D fields. This presentation will introduce Seegene’s unique syndromic assay development platform and how it can be used to open the new era of MDx.